Spots Global Cancer Trial Database for tp53
Every month we try and update this database with for tp53 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TL-895 and KRT-232 Study in Acute Myeloid Leukemia | NCT04669067 | Acute Myeloid L... | TL-895 KRT-232 | 18 Years - | Telios Pharma, Inc. | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | NCT05778149 | Aumolertinib Anlotinib TP53 NSCLC EGFR Activating... | Aumolertinib,An... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| The p53 Breast Cancer Trial | NCT02965950 | Locally Advance... Metastatic Brea... | Cyclophosphamid... | 18 Years - | Haukeland University Hospital | |
| The p53 Breast Cancer Trial | NCT02965950 | Locally Advance... Metastatic Brea... | Cyclophosphamid... | 18 Years - | Haukeland University Hospital | |
| Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | NCT05778149 | Aumolertinib Anlotinib TP53 NSCLC EGFR Activating... | Aumolertinib,An... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Li-Fraumeni Syndrome/TP53 Biobank | NCT04367246 | Li-Fraumeni Syn... Li-Fraumeni-Lik... | No Intervention | - | Abramson Cancer Center at Penn Medicine | |
| Clinical and Genetic Studies of Li-Fraumeni Syndrome | NCT01443468 | Li-Fraumeni Syn... Neoplasms Tp53 Mutations | - | National Institutes of Health Clinical Center (CC) | ||
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | NCT04358393 | AML Acute Myeloid L... Chronic Myelomo... CMML Myelodysplastic... High-risk Myelo... MDS | APG-115 5-azacitidine | 18 Years - | Ascentage Pharma Group Inc. | |
| Li-Fraumeni Syndrome/TP53 Biobank | NCT04367246 | Li-Fraumeni Syn... Li-Fraumeni-Lik... | No Intervention | - | Abramson Cancer Center at Penn Medicine | |
| AZA Combined With RCHOP in P53-mutated DLBCL. | NCT06158399 | DLBCL - Diffuse... TP53 | Azacitidine in ... | 18 Years - 70 Years | The First Affiliated Hospital of Xiamen University | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia | NCT02827617 | Chronic Lymphoc... | Ibrutinib | 18 Years - | Oncology Institute of Southern Switzerland | |
| A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer | NCT02797964 | Advanced Solid ... | SRA737 | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Li-Fraumeni Syndrome/TP53 Biobank | NCT04367246 | Li-Fraumeni Syn... Li-Fraumeni-Lik... | No Intervention | - | Abramson Cancer Center at Penn Medicine | |
| Prognostic Biomarkers in Patients With Urothelial Carcinoma | NCT04872036 | Bladder Cancer | 18 Years - | Hellenic Cooperative Oncology Group | ||
| Advanced Refractory Solid Tumors With TP53 Mutations Register Study | NCT03927599 | Solid Tumor, Ad... | Data Collection | 18 Years - | Tianjin Medical University Second Hospital | |
| Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC | NCT06369181 | Neuroendocrine ... Non-small Cell ... Histology Trans... | 18 Years - | Fudan University | ||
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | NCT04358393 | AML Acute Myeloid L... Chronic Myelomo... CMML Myelodysplastic... High-risk Myelo... MDS | APG-115 5-azacitidine | 18 Years - | Ascentage Pharma Group Inc. | |
| ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab | NCT06366347 | Endometrial Can... Recurrent Endom... TP53 | Abemaciclib Letrozole Pembrolizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer | NCT02797964 | Advanced Solid ... | SRA737 | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT | NCT04123392 | TP53 Myeloid Tumors Conditioning Allogeneic Hema... | Decitabine Busulfan (BU) Cyclophosphamid... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Treatment of Carrying TP53 Harmful Mutations | NCT03645200 | Advanced Cancer | Fluzoparib comb... | 18 Years - 70 Years | Tianjin Medical University Second Hospital | |
| Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer | NCT01914900 | Locally Advance... | docetaxel, cisp... | 18 Years - 99 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT | NCT04123392 | TP53 Myeloid Tumors Conditioning Allogeneic Hema... | Decitabine Busulfan (BU) Cyclophosphamid... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Prognostic Biomarkers in Patients With Urothelial Carcinoma | NCT04872036 | Bladder Cancer | 18 Years - | Hellenic Cooperative Oncology Group | ||
| Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53 | NCT04966923 | Breast Cancer TP53 R337H Li-Fraumeni Syn... Prognosis Breas... | No intervention... | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| The p53 Breast Cancer Trial | NCT02965950 | Locally Advance... Metastatic Brea... | Cyclophosphamid... | 18 Years - | Haukeland University Hospital | |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | NCT04477291 | Acute Myeloid L... Myelodysplastic... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| AZA Combined With RCHOP in P53-mutated DLBCL. | NCT06158399 | DLBCL - Diffuse... TP53 | Azacitidine in ... | 18 Years - 70 Years | The First Affiliated Hospital of Xiamen University | |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | NCT05735717 | Hematologic Mal... Acute Leukemia Remission Acute Myeloid L... Acute Lymphobla... AML TP53 Intrachromosoma... Cytogenetic Abn... CNS Leukemia Minimal Residua... Myelodysplasia Juvenile Myelom... Somatic Mutatio... PTPN11 Gene Mut... N-RAS Gene Ampl... Neurofibromatos... NF1 Mutation CBL Gene Mutati... Monosomy 7 Chromosome Abno... Fetal Hemoglobi... | Fludarabine Busulfan Melphalan Rituximab Levetiracetam | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma | NCT04533321 | Squamous Cell C... | Afatinib | 21 Years - 99 Years | National University Hospital, Singapore |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
